Clinical Trials Directory

Trials / Completed

CompletedNCT00905515

Optima: Optimizing Prograf Therapy in Maintenance Allografts II

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
63 (actual)
Sponsor
East Carolina University · Academic / Other
Sex
All
Age
18 Years – 85 Years
Healthy volunteers
Not accepted

Summary

This study is designed to optimize calcineurin immunosuppressive regimens and evaluate immunological and non-immunological markers that may explain mechanistic differences in these agents and their effects.

Detailed description

One of the major challenges in transplantation over the past two decades has been managing long-term renal function. Serum creatinine is the most commonly used serum marker of renal function. However serum creatinine is insensitive for detecting small decreases in glomerular filtration rate (GFR). Another marker for renal function is cystatin C. Dharnidharka et al concluded that cystatin C is superior to serum creatinine as a marker of kidney function since cystatin C was a more sensitive marker than serum creatinine for detecting decreases in GFR. Pirsch et al reported that tacrolimus-treated patients had a lower incidence of severe acute rejection and better lipid profiles than cyclosporine-treated patients. Cardiovascular disease is the primary cause of premature death in renal and other transplant recipients. Current immunosuppressive protocols often elevate cardiovascular disease risk factors such as hypertension, hyperlipidemia, obesity and diabetes. This study is designed to optimize calcineurin immunosuppressive regimens to ensure the best possible long-term outcomes after renal transplantation.

Conditions

Interventions

TypeNameDescription
DRUGcyclosporineMaintain on cyclosporine at target trough level of 50-250 ng/mL.
DRUGPrograf (Tacrolimus)Convert to Prograf at target trough levels of 3.0-5.9 ng/mL (Arm 2) or target trough levels of 6.0-8.9 ng/mL (Arm 3).

Timeline

Start date
2003-08-01
Primary completion
2008-07-01
Completion
2008-07-01
First posted
2009-05-20
Last updated
2023-09-07
Results posted
2013-02-11

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00905515. Inclusion in this directory is not an endorsement.